Dr Reddy’s Laboratories’ subsidiary, Aurigene Oncology Limited, received DCGI approval to conduct a phase-2 trial for India’s first novel autologous BCMA directed CAR-T cell therapy, Ribrecabtagene autoleucel, following promising phase-1 results showing significant clinical response in patients with relapsed or refractory multiple myeloma.
Related Posts
Hospitals garner 50% share in healthcare FDI
India’s healthcare sector, particularly hospitals, has witnessed a surge in foreign direct investment, reaching $1.5 billion in FY24. This represents a significant increase, more than […]
EPS first company to get white-label ATM licence from RBI in a decade
Electronic Payment and Services (EPS) becomes the fifth entity to secure a license for white-label ATMs (WLAs) in India, aiming to roll out 9,000 ATMs […]
Sri Lanka’s key consumer price index falls 2.1% in November
Sri Lanka’s consumer price index fell by 2.1% year-on-year in November, marking the lowest inflation point in nine years. Declines in power tariffs, fuel prices, […]